TITLE

Rosuvastatin no better than atorvastatin

AUTHOR(S)
Elliott, William T.
PUB. DATE
November 2011
SOURCE
Travel Medicine Advisor;Nov2011 Supplement, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article informs of a study which compares the effectiveness of rosuvastanin, a drug class of statins, with another drug class of statins, atorvastanin, and states that the effectiveness of rosuvastanin is no better than atorvastanin in treating coronary atheroma, a coronary artery disease.
ACCESSION #
68638045

 

Related Articles

  • Talking point.  // Pulse;Aug2013, p15 

    The article presents questions and answers related to the study which investigates the benefits and safety of statins in treating coronary heart disease (CHD), conducted by the West Scotland Coronary Prevention Study (WOSCOPS.)

  • Latest Research.  // Medical Economics;1/8/2010, Vol. 87 Issue 1, p34 

    The article features the study made by Beth Israel Deaconess Medical Center on the efficacy of high-dose statin treatment in reducing cardiovascular events in patients in Boston, Massachusetts. Researchers found that those to take 80 milligrams of atorvastatin lowers myocardial infarction,...

  • Catestatin reduces myocardial ischaemia/reperfusion injury: involvement of PI3K/Akt, PKCs, mitochondrial K channels and ROS signalling. Perrelli, Maria-Giulia; Tullio, Francesca; Angotti, Carmelina; Cerra, Maria; Angelone, Tommaso; Tota, Bruno; Alloatti, Giuseppe; Penna, Claudia; Pagliaro, Pasquale // Pflugers Archiv European Journal of Physiology;Jul2013, Vol. 465 Issue 7, p1031 

    Catestatin (CST) limits myocardial ischaemia/reperfusion (I/R) injury with unknown mechanisms. Clearly phosphoinositide-3-kinase (PI3K), protein kinase C (PKC) isoforms, including intra-mitochondrial PKCε, mitochondrial K (mitoK) channels and subsequent reactive oxygen species...

  • Effects of Statins on Serum n-3 to n-6 Polyunsaturated Fatty Acid Ratios in Patients With Coronary Artery Disease. Nozue, Tsuyoshi; Yamamoto, Shingo; Tohyama, Shinichi; Fukui, Kazuki; Umezawa, Shigeo; Onishi, Yuko; Kunishima, Tomoyuki; Sato, Akira; Nozato, Toshihiro; Miyake, Shogo; Takeyama, Youichi; Morino, Yoshihiro; Yamauchi, Takao; Muramatsu, Toshiya; Hibi, Kiyoshi; Michishita, Ichiro // Journal of Cardiovascular Pharmacology & Therapeutics;Jul2013, Vol. 18 Issue 4, p320 

    Background: A low n-3 to n-6 polyunsaturated fatty acids (PUFAs) ratio is reported to be associated with cardiovascular events.However, the effects of statins on this ratio have not been fully examined. Methods: A total of 101 patients with coronary arterydisease, who were not receiving...

  • The Effect of Alternative Summary Statistics for Communicating Risk Reduction on Decisions about Taking Statins: A Randomized Trial. Carling, Cheryl L. L.; Kristoffersen, Doris Tove; Montori, Victor M.; Herrin, Jeph; Schünemann, Holger J.; Treweek, Shaun; Akl, Elie A.; Oxman, Andrew D. // PLoS Medicine;Aug2009, Vol. 6 Issue 8, p1 

    Background: While different ways of presenting treatment effects can affect health care decisions, little is known about which presentations best help people make decisions consistent with their own values. We compared six summary statistics for communicating coronary heart disease (CHD) risk...

  • Clinical briefs.  // New Zealand Doctor;12/15/2010, p19 

    This section offers news briefs on clinical studies as of December 15, 2010 including the effectiveness of using ezetimibe in addition to a statin to reduce vascular events in patients with cardiovascular disease, capability of eplerenone to reduce the risk of death and hospitalisation in...

  • Statins - from bench to bedside. Gheorghe, Gabriela Silvia; Hodorogea, Andreea Simona; Nanea, Ioan Tiberiu // Romanian Journal of Cardiology;2014, Vol. 24 Issue 3, p170 

    Statins are probably the most prescribed drugs in cardiology worldwide, with evident efficiency in primary and secondary prevention. They act on the first step of cholesterol synthesis by blocking the hepatic hydoxi methyl glutaril coenzyme A (HMG CoA) reductase dose-dependent, reversible and...

  • PLATO: Ticagrelor associated with reduced outcomes, mortality in patients with ACS.  // Cardiology Today;Feb2010, Vol. 13 Issue 2, p18 

    The article discusses research on the efficacy of ticagrelor in reducing mortality in patients with acute coronary syndromes, with a reference to a study by C. P. Cannon that was published in an issue of "Lancet."

  • New developments in P2Y12 antagonists. Michelson, Alan D. // Hem/Onc Today;7/10/2009, Vol. 10 Issue 13, p4 

    This article discusses the efficacy and safety of clopidogrel in treating patients with a syndrome.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics